Introduction
============

Type 2 diabetes mellitus (T2DM) is a common chronic health condition in the elderly. The number of elderly T2DM patients has been growing worldwide, especially in upper-middle income countries such as Thailand. Based on the findings of the Fourth Thai National Health Examination Survey in 2009, diabetes was most prevalent in women, the elderly, and urban areas. The prevalence of impaired fasting glucose and undiagnosed diabetes increased with age, peaking at age ≥75 years and 55--64 years, respectively.[@b1-ceor-8-521] Diabetes in the elderly is associated with a greater risk of T2DM-related micro- and macrovascular complications, cognitive disorders, physical disability, morbidity, and mortality;[@b2-ceor-8-521]--[@b5-ceor-8-521] the selection of antidiabetic treatment for elderly T2DM patients poses many challenges for a number of reasons. First, elderly T2DM patients have a greater incidence of hypoglycemia[@b6-ceor-8-521] which can precipitate serious events such as falls and accompanying fractures. The study by Zhao et al[@b7-ceor-8-521] showed that hypoglycemia patients had higher rates of fall-related fractures than those without hypoglycemia, within 30 days and 1 year (0.64% vs 0.02% and 2.11% vs 0.50%, respectively). Second, elderly T2DM patients are more likely to have comorbidities with their diabetes, leading to the use of polypharmacy.[@b4-ceor-8-521],[@b8-ceor-8-521],[@b9-ceor-8-521] Third, chronic kidney disease often occurs in elderly T2DM patients;[@b10-ceor-8-521] the prevalence of chronic kidney disease among T2DM patients in Australia,[@b11-ceor-8-521] India,[@b12-ceor-8-521] Finland,[@b13-ceor-8-521] Singapore,[@b14-ceor-8-521] and the US[@b15-ceor-8-521] ranged from 40% to 70%. With these associated challenges for elderly T2DM patients, finding effective and safe therapeutic agents is very crucial.

Dipeptidyl peptidase-4 (DPP-4) inhibitors show particular promise for treating elderly T2DM patients because they have excellent tolerability profiles, low risk of hypoglycemia, and little effect on body weight.[@b4-ceor-8-521],[@b16-ceor-8-521],[@b17-ceor-8-521] Therefore, this study evaluated the cost-effectiveness of DPP-4 inhibitor monotherapy compared with sulfonylurea (SFU) monotherapy or metformin monotherapy for treating elderly T2DM patients in the Thai context.

Methods
=======

Study design and cohort population
----------------------------------

From a Thai health care system perspective, we conducted a cost-utility analysis and used a validated IMS CORE Diabetes Model (CDM), Version 8.5, to estimate long-term costs and outcomes associated with each treatment over a lifetime horizon. Details of this model are described elsewhere.[@b18-ceor-8-521],[@b19-ceor-8-521] A 3% discount rate per annum was applied to both costs and outcomes in line with the Thai Health Technology Assessment (HTA) guideline.[@b20-ceor-8-521]

The cohort population was Thai people with T2DM aged at least 65 years. [Table 1](#t1-ceor-8-521){ref-type="table"} presents the baseline demographics, risk factors, and clinical complications of the cohort, which were obtained from published data and hospital databases in Thailand.[@b21-ceor-8-521]--[@b28-ceor-8-521] The all-cause mortality rate was also adjusted with the age-specific mortality rate of Thai people.[@b29-ceor-8-521] Utility values used in the CDM were based mostly on published studies conducted in other countries.[@b30-ceor-8-521]--[@b34-ceor-8-521]

This study was approved by the Buddhachinaraj Regional Hospital Ethics Committee on August 8, 2014. As the patient data is de-identified patient consent was not required.

Interventions in the study
--------------------------

Our study considered the following DPP-4 inhibitors: saxagliptin, sitagliptin, and vildagliptin. These medications were administered as a monotherapy and then compared with either metformin monotherapy or SFU monotherapy. We used metformin and SFU (glipizide) as comparators for several reasons. First, the Thai HTA guideline[@b35-ceor-8-521] recommends current practice as a comparator. Metformin and SFU are considered as usual care for elderly T2DM patients in Thailand. Second, we convened a panel of stakeholders to discuss the scope and appropriate comparators of the study, including endocrinologists, and policy makers, and then followed the consensus of the meeting. This study used the normal daily dose of each treatment option: saxagliptin (5 mg), sitagliptin (100 mg), vildagliptin (100 mg), glipizide (10 mg), and metformin (2,000 mg).

Costs
-----

Only the direct medical costs, such as cost of intervention, concurrent medications, diabetic screening, management, and treatment complications, were included in the cost-effectiveness analysis. Cost data were derived from the published literature and retrospective hospital database analyses ([Table 2](#t2-ceor-8-521){ref-type="table"}).[@b36-ceor-8-521]--[@b41-ceor-8-521] All costs were inflated using Thailand's consumer price index[@b42-ceor-8-521] and presented in the year 2014 THB value. Costs were converted to US\$ at a rate of THB32.96 per US\$ as of December 30, 2014.[@b43-ceor-8-521]

The cost of DPP-4 inhibitors was proposed to the subcommittee for the development of the National List of Essential Medicine by the pharmaceutical companies. Total cost per year of saxagliptin, sitagliptin, and vildagliptin was THB13,492 (US\$409.34), THB16,570 (US\$502.73), and THB15,900 (US\$482.40), respectively. Glipizide and metformin have several generic products in Thailand. We used a median of the median prices of those generic products[@b44-ceor-8-521] as recommended by the Thai HTA guideline.[@b45-ceor-8-521] The annual total costs of metformin and SFU were THB496 (US\$15.05) and THB149 (US\$4.52), respectively.

Treatment efficacy and adverse events
-------------------------------------

Due to limited evidence of treatment efficacy in Thailand, we performed a systematic review and meta-analysis to estimate the pooled efficacy of DPP-4 inhibitor monotherapy compared to SFU monotherapy and metformin monotherapy in elderly T2DM patients. The MEDLINE, EMBASE, and [Clinicaltrial.gov](http://Clinicaltrial.gov) databases were systematically searched from their inception to August 2014. We found only one study[@b46-ceor-8-521] that indicated noninferiority of alogliptin compared to glipizide in HbA~1c~ reduction (the weighted mean difference −0.09; 95% CI, −∞ to 0.06), substantially lower risk of hypoglycemia (risk ratio \[RR\] 0.21; 95% CI, 0.11--0.41), lower risk of severe hypoglycemia (RR 0.23; 95% CI, 0.03--1.99), and no weight gain with DPP-4 inhibitor monotherapy compared to glipizide monotherapy in elderly T2DM patients ([Table 3](#t3-ceor-8-521){ref-type="table"}).

Three studies[@b5-ceor-8-521],[@b47-ceor-8-521],[@b48-ceor-8-521] compared metformin with DPP-4 inhibitor monotherapy and concluded that DPP-4 inhibitor was an effective and well-tolerated treatment option for elderly T2DM patients. In addition, reduction in HbA~1c~ after treatment with DPP-4 inhibitors in elderly T2DM patients was not significantly different from those in younger patients.[@b49-ceor-8-521] Therefore, we decided to systematically search a meta-analysis study that compared DPP-4 inhibitor monotherapy with metformin monotherapy in T2DM patients, and found two eligible studies.[@b50-ceor-8-521],[@b51-ceor-8-521] Both were high quality studies (with scores of at least 9 of 11) based on the Assessment of Multiple Systematic Reviews, We decided to use Wu et al's[@b51-ceor-8-521] meta-analysis as it was the most up-to-date. The efficacy of HbA~1c~ reduction from the baseline of metformin monotherapy was estimated from the pooled analysis of seven studies[@b48-ceor-8-521],[@b52-ceor-8-521]--[@b57-ceor-8-521] included in the meta-analysis of Wu et al.[@b51-ceor-8-521] Of those studies,[@b48-ceor-8-521],[@b52-ceor-8-521]--[@b57-ceor-8-521] severe hypoglycemia was presented in two studies,[@b52-ceor-8-521],[@b55-ceor-8-521] for which the RR was estimated. The calculation details are shown in [Table 3](#t3-ceor-8-521){ref-type="table"}.

Sensitivity analyses
--------------------

To determine the robustness of the findings, we undertook a probabilistic sensitivity analysis and presented the relationship between the probability of favoring DPP-4 inhibitors and the value of the willingness to pay for an additional unit of quality-adjusted life year (QALY) as a cost-effectiveness acceptability curve. The current acceptable Thai ceiling threshold of THB160,000/QALY (US\$4,854.37/QALY) was recommended by the subcommittee for the development of the universal health coverage benefit package and service delivery in Thailand.[@b58-ceor-8-521] A series of one-way sensitivity analyses were also performed to determine the effect of HbA~1c~ change, risk of hypoglycemia, drug cost, and discount rate. The results were displayed as a Tornado diagram.

Results
=======

Base-case analysis
------------------

In the base-case scenario, all three DPP-4 inhibitors incurred higher costs and yielded fewer QALYs (5.965 QALYs vs 5.986 QALYs). In other words, all DPP-4 inhibitors were dominated, making metformin monotherapy a cost-saving treatment in elderly T2DM patients in Thai context ([Table 4](#t4-ceor-8-521){ref-type="table"}).

All three DPP-4 inhibitors were more effective (equal 0.031 higher QALYs) but more costly than SFU. Saxagliptin yielded the lowest incremental cost per QALY, followed by vildagliptin and sitagliptin (THB3,632,604/QALY or US\$110,212.50/QALY, THB4,335,273/QALY or US\$131,531.34/QALY, and THB4,530,556/QALY or US\$137,456.19/QALY, respectively). With the current Thai threshold of THB160,000/QALY (US\$4,854.37/QALY), DPP-4 inhibitors were not cost-effective compared to SFU for treating elderly T2DM patients in the Thai context ([Table 4](#t4-ceor-8-521){ref-type="table"}).

Sensitivity analyses
--------------------

As vildagliptin and sitagliptin were dominated by saxagliptin, the results of one-way sensitivity analysis, therefore, were displayed on saxagliptin compared to SFU. The change in HbA~1c~ from the baseline of DPP-4 inhibitors, discount rate, risk of severe hypoglycemia, and cost of saxagliptin had some effect on the incremental cost-effectiveness ratio (ICER) ([Figure 1](#f1-ceor-8-521){ref-type="fig"}). The greater the effect of DPP-4 inhibitors on the reduction of HbA~1c~ from baseline, the lower ICER ([Figure 1](#f1-ceor-8-521){ref-type="fig"}). Based on the cost-effectiveness acceptability curve ([Figure 2](#f2-ceor-8-521){ref-type="fig"}), all DPP-4 inhibitors were not a cost-effective treatment compared to SFU at the ceiling threshold of 160,000 THB/QALY. Compared to metformin, the probability of DPP-4 inhibitors being cost-effective was even smaller than being compared to SFU.

Discussion
==========

Elderly patients with diabetes have an increased risk of T2DM-related morbidity and mortality. The treatment goal for elderly T2DM patients is to optimize glycemic control while minimizing the risk of drug-associated adverse events. Thus, this study was conducted to generate economic evidence of DPP-4 inhibitors for T2DM treatment in response to a request by the subcommittee for the development of the National List of Essential Medicine in 2014. The findings of the study were submitted and presented to the subcommittee in 2015 to justify policy decision in terms of the value for money. This cost-effectiveness study followed the Thai national HTA guideline.[@b59-ceor-8-521] Our findings indicated that DPP-4 inhibitor monotherapy was not a cost-effective treatment for elderly T2DM patients in Thailand compared to either SFU monotherapy or metformin monotherapy. Efficacy in HbA~1c~ reduction, risk of severe hypoglycemia, and cost of DPP-4 inhibitors play an important role in the findings of the study.

We are not aware of other studies evaluating the cost-effectiveness of DPP-4 inhibitor monotherapy in elderly T2DM patients. Geng et al[@b60-ceor-8-521] conducted a systematic review of cost-effectiveness of DPP-4 inhibitors for treating T2DM; the eleven included studies assessed DPP-4 inhibitors as an add-on therapy. Of those, seven studies compared DPP-4 inhibitors and metformin with SFU and metformin. Six studies concluded that DPP-4 inhibitors were cost-effective compared to SFU for treating T2DM patients for whom metformin monotherapy failed to achieve glycemic control.

Our study was strengthened by incorporating input parameters, such as costs, baseline cohort characteristics, and adverse events, from data sources that were reliable and relevant to the Thai context. Similarly, it is important to point out some potential limitations of our study. First, based on our systematic review, we found only one study[@b46-ceor-8-521] that evaluated the efficacy and safety of a DPP-4 inhibitor monotherapy compared to SFU monotherapy in elderly T2DM patients. This study indicated noninferiority in HbA~1c~ reduction but a lower risk of hypoglycemia and no weight gain with the DPP-4 inhibitor monotherapy compared to SFU monotherapy. Only three studies[@b5-ceor-8-521],[@b47-ceor-8-521],[@b48-ceor-8-521] compared DPP-4 inhibitor monotherapy with metformin monotherapy in elderly T2DM patients. However, HbA~1c~ reduction after treatment with DPP-4 inhibitors was not significantly different in elderly T2DM patients vs younger T2DM patients.[@b49-ceor-8-521] We addressed this limitation by the pooled analysis of seven studies[@b48-ceor-8-521],[@b52-ceor-8-521]--[@b57-ceor-8-521] included in the meta-analysis study by Wu et al[@b51-ceor-8-521] that compared metformin monotherapy with DPP-4 inhibitor monotherapy in T2DM patients. Second, we tried our best to use resource utilization and cost data from Thailand. Some cost data were not available, such as the cost of an infected ulcer; we assumed them equal to zero. We reanalyzed our base-case analysis, assuming the cost of an infected ulcer similar to an uninfected ulcer. The results showed a slightly lower ICER from THB3,632,604/QALY (US\$110,212.50/QALY) to THB3,630,697/QALY (US\$110,154.64/QALY) comparing saxagliptin to SFU. Metformin monotherapy was still a dominant treatment compared to DPP-4 inhibitor monotherapy, when assuming equal cost of an infected and uninfected ulcer. The availability of local evidence is another limitation. Even though costs, baseline cohort characteristics, and adverse events were obtained from published studies or hospital databases in Thailand, this study relies on utility values and transition probabilities within the CDM from studies conducted in other countries. Given these limitations, the confirmation of this study's findings may be premature. However, the findings indicate that treating elderly T2DM patients using DPP-4 inhibitor monotherapy in a Thai context may not be cost-effective.

Conclusion
==========

For treating elderly T2DM patients in Thailand, DPP-4 inhibitor monotherapy is not a cost-effective treatment compared to metformin monotherapy. In addition, DPP-4 inhibitor monotherapy is not a cost-effective treatment compared to SFU monotherapy at the current Thai threshold of THB160,000/QALY. The high acquisition cost of DPP-4 inhibitors is one of the key factors in the findings of this study.
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###### 

Baseline characteristics of the cohort population

  Variables                                       Mean ±SD     Data sources
  ----------------------------------------------- ------------ -----------------------------------------------------
  Patient demographics                                         
   Mean age (years)                               72.8±5.6     BCRH database
   Duration of diabetes (years)                   10.5±7.6     TDR2006[@b21-ceor-8-521]
   Proportion male                                34.3%        BCRH database
  Risk factors                                                 
   HbA~1c~ level (%)                              7.9±6.6      BCRH database
   Systolic blood pressure (mmHg)                 143.6±22.4   TDR2006[@b21-ceor-8-521]
   Total cholesterol (mg/dL)                      187.4±45.4   BCRH database
   High-density lipoprotein cholesterol (mg/dL)   49.8±15.1    BCRH database
   Low-density lipoprotein cholesterol (mg/dL)    108.3±39.5   BCRH database
   Triglycerides (mg/dL)                          169.8±95.6   BCRH database
   Body mass index (kg/m^2^)                      24.6±4.1     Trongsakul[@b22-ceor-8-521]
   eGFR (mL/min/1.73 m^2^)                        66.6±28.5    BCRH database
  Proportion of smokers                           8.10%        Trongsakul[@b22-ceor-8-521]
  Number of cigarettes smoked per day             6.0          Porapakkham and Plattara-Archachai[@b23-ceor-8-521]
  Alcohol consumption (mL/wk)                     136.5        Center of Alcohol Studies[@b24-ceor-8-521]
  Cardiovascular disease complications                         
   Myocardial infarction                          2.4%         BCRH database
   Angina pectoris                                1.3%         BCRH database
   Peripheral vascular disease                    0.2%         BCRH database
   Stroke                                         2.5%         BCRH database
   Congestive heart failure                       4.7%         BCRH database
   Atrial fibrillation                            2.5%         BCRH database
   Left ventricular hypertrophy                   0.3%         BCRH database
  Cataract                                        42.8%        TDR2006[@b21-ceor-8-521]
  Depression                                      19.4%        Thaneerat and Tangwongchai [@b25-ceor-8-521]
  Foot ulcer complications                                     
   Uninfected ulcer                               5.9%         TDR2003[@b26-ceor-8-521]
   Infected ulcer                                 1.2%         Nitiyanant et al[@b27-ceor-8-521]
   Healed ulcer                                   6.9%         Nitiyanant et al[@b27-ceor-8-521]
   History of amputation                          1.5%         TDR2006[@b21-ceor-8-521]
  Macular edema                                   2.5%         Supapluksakul et al[@b28-ceor-8-521]
  Neuropathy                                      2.1%         BCRH database
  Renal complications                                          
   Microalbuminuria                               18.0%        TDR2006[@b21-ceor-8-521]
   Gross proteinuria                              26.1%        TDR2006[@b21-ceor-8-521]
   End-stage renal disease                        0.1%         Nitiyanant et al[@b27-ceor-8-521]
  Retinopathy complications                                    
   Background retinopathy                         22.0%        TDR2006[@b21-ceor-8-521]
   Proliferative retinopathy                      9.4%         TDR2006[@b21-ceor-8-521]
   Severe vision loss                             1.5%         TDR2006[@b21-ceor-8-521]

**Abbreviations:** BCRH, Buddhachinaraj Regional Hospital; SD, standard deviation; TDR, Thailand diabetes registry.

###### 

Cost parameters used in the CDM

  Variables                                    Mean (THB)   SD           Reference
  -------------------------------------------- ------------ ------------ -------------------------------------------------------
  Management costs                                                       
   Aspirin                                     185          119.58       BCRH database
   Statin                                      2,042        4,956.59     BCRH database
   ACEI                                        1,319        3,037.85     BCRH database
   Antidepressant                              2,323        6,107.65     BCRH database
   Screening for microalbuminuria              320          --           Maharaj Nakorn Chiang Mai hospital[@b36-ceor-8-521]
   Screening for gross proteinuria             60           --           Maharaj Nakorn Chiang Mai hospital[@b36-ceor-8-521]
   Eye screening                               129          --           Pornpinatepong [@b37-ceor-8-521]
   Foot screening program                      70           --           Standard cost list[@b38-ceor-8-521]
  Costs of acute events                                                  
   Major hypoglycemia                          27,856       70,785.76    BCRH database
   Ketoacidosis event                          13,284       36,398.48    BCRH database
   Lactic acidosis event                       64,724       97,511.56    BCRH database
   Major hypoglycemia                          27,856       70,785.76    BCRH database
  Costs of eye diseases                                                  
   Laser treatment                             1,920        --           Pornpinatepong[@b37-ceor-8-521]
   Cataract operation                          7,000        --           National Health Security Office[@b39-ceor-8-521]
   Blindness, first year                       30,902       17,675.91    BCRH database
   Blindness, subsequent years                 18,766       32,900.26    BCRH database
  Costs of cardiovascular complications                                  
   MI, first year                              106,323      129,552.60   BCRH database
   MI, subsequent years                        26,629       41,451.42    BCRH database
   Angina first year                           60,235       83,594.51    BCRH database
   Angina, subsequent years                    19,578       28,308.46    BCRH database
   CHF, first year                             58,875       79,235.18    BCRH database
   CHF, subsequent years                       25,452       39,122.61    BCRH database
   Stroke, first year                          71,362       --           BCRH database
   Stroke, subsequent years                    23,884       32,123.49    BCRH database
   Stroke death within 30 days                 38,189       41,778       BCRH database
   PVD, first year                             156,394      276,600.00   BCRH database
   PVD, subsequent years                       50,374       50,253.25    BCRH database
  Costs of neuropathy and foot complications                             
   Neuropathy, first year                      24,410       37,763.1     BCRH database
   Neuropathy, subsequent years                18,797       28,631.95    BCRH database
   Amputation                                  48,365       --           BCRH database
   Gangrene treatment (yearly)                 76,950       95,163.4     BCRH database
   Infected ulcer                              0            --           Assumption
   Uninfected ulcer (yearly)                   53,076       74,776.36    BCRH database
  Costs of renal complications                                           
   HD, first year                              452,120      --           Teerawattananon et al[@b40-ceor-8-521]
   HD, subsequent years                        428,141      --           Teerawattananon et al[@b40-ceor-8-521]
   PD, first year                              460,129      --           Teerawattananon et al[@b40-ceor-8-521]
   PD, subsequent years                        408,080      --           Teerawattananon et al[@b40-ceor-8-521]
   RT, first year                              928,000      --           King Chulalongkorn Memorial Hospital[@b41-ceor-8-521]
   RT, subsequent years                        429,240      --           King Chulalongkorn Memorial Hospital[@b41-ceor-8-521]

**Note:** The dash indicates no data available.

**Abbreviations:** ACEI, angiotensin-converting-enzyme inhibitor; BCRH, Buddhachinaraj Regional Hospital; CDM, IMS CORE Diabetes Model, Version 8.5; CHF, congestive heart failure; HD, hemodialysis; MI, myocardial infarction; PD, peritoneal dialysis; PVD, peripheral vascular disease; RT, renal transplant; SD, standard deviation; THB, Thai Baht.

###### 

Efficacy and adverse effects of DPP-4 inhibitors, metformin, and SFU

  Variables                                                                          Mean (95% CI)          Data sources
  ---------------------------------------------------------------------------------- ---------------------- ------------------------------------------------------------
  Efficacy                                                                                                  
   HbA~1c~ reduction (%)                                                                                    
    DPP-4 inhibitors vs placebo                                                      −0.92 (−0.8, −1.03)    Calculation[a](#tfn4-ceor-8-521){ref-type="table-fn"}
    Metformin vs placebo                                                             −1.20 (−0.81, −1.59)   Pooled analysis[b](#tfn5-ceor-8-521){ref-type="table-fn"}
    SFU vs placebo                                                                   −0.83 (−0.98, 0)       Calculation[c](#tfn6-ceor-8-521){ref-type="table-fn"}
    Weighted mean difference (%) (DPP-4 inhibitors vs metformin), favor metformin    0.28 (0.17, 0.40)      Wu et al[@b51-ceor-8-521]
    Weighted mean difference (%) (DPP-4 inhibitors vs SFU), favor DPP-4 inhibitors   −0.09 (--∞, 0.06)      Rosenstock et al[@b46-ceor-8-521]
  Adverse effects                                                                                           
   Risk of severe hypoglycemia (%)                                                                          
    SFU                                                                              2.44                   BCRH database
    DPP-4 inhibitors                                                                 0.55 (0.32, 4.87)      Calculation[d](#tfn7-ceor-8-521){ref-type="table-fn"}
    Metformin                                                                        0.55 (0.32, 4.87)      Assumption[e](#tfn8-ceor-8-521){ref-type="table-fn"}
   Risk of symptomatic hypoglycemia (%)                                                                     
    SFU                                                                              19.36                  RECAP-DM study[@b61-ceor-8-521]
    DPP-4 inhibitors                                                                 4.14 (2.15, 7.99)      Calculation[f](#tfn9-ceor-8-521){ref-type="table-fn"}
    Metformin                                                                        9.41 (5.75, 15.33)     Calculation[g](#tfn10-ceor-8-521){ref-type="table-fn"}
   Risk ratio of severe hypoglycemia (DPP-4 inhibitors vs SFU)                       0.225 (0.03, 1.99)     Rosenstock et al[@b46-ceor-8-521]
   Risk ratio of severe hypoglycemia (DPP-4 inhibitors vs metformin)                 0.25 (0.03, 2.19)      Pooled analysis[h](#tfn11-ceor-8-521){ref-type="table-fn"}
   Risk ratio of symptomatic hypoglycemia (DPP-4 inhibitors vs SFU)                  0.214 (0.11, 0.41)     Rosenstock et al[@b46-ceor-8-521]
   Risk ratio of symptomatic hypoglycemia (DPP-4 inhibitors vs metformin)            0.44 (0.27, 0.72)      Wu et al[@b51-ceor-8-521]

**Notes:**

HbA~1c~ reduction from baseline of DPP-4 inhibitors =−0.92 (−1.20+0.28). Upper 95% CI =−1.03 (−1.2+0.17) and lower 95% CI =−0.8 (−1.2+0.4).

Estimate the efficacy of metformin from the pooled analysis of seven studies[@b40-ceor-8-521],[@b44-ceor-8-521]--[@b49-ceor-8-521] included in the meta-analysis by Wu et al.[@b51-ceor-8-521]

HbA~1c~ reduction from baseline of SFU =−0.83 (−0.92+0.09). Upper 95% CI assumed to be =0 (−0.92+∞), lower 95% CI =−0.98 (−0.92−0.06).

Risk of severe hypoglycemia of DPP-4 inhibitors =0.55% (2.44%×0.225).

Risk of severe hypoglycemia of DPP-4 inhibitors was assumed to be equal to that of metformin.

Risk of symptomatic hypoglycemia of DPP-4 inhibitors =4.14% (19.36%×0.214),

Risk of symptomatic hypoglycemia of metformin =9.41% (4.14%/0.44).

Estimate risk ratio of severe hypoglycemia from the pooled analysis of two studies[@b52-ceor-8-521],[@b55-ceor-8-521] included in the meta-analysis by Wu et al.[@b51-ceor-8-521]

**Abbreviations:** BCRH, Buddhachinaraj Regional Hospital; DPP-4, dipeptidyl peptidase-4; SFU, sulfonylurea.

###### 

Results of DPP-4 inhibitor monotherapy versus metformin monotherapy or SFU monotherapy in base-case analysis

  Treatment                      Total cost, THB (US\$)   Quality-adjusted life year   Incremental costs, THB (US\$)   Incremental effectiveness (QALYs gained)   Incremental cost-effectiveness ratio, THB/QALY (US\$/QALY)
  ------------------------------ ------------------------ ---------------------------- ------------------------------- ------------------------------------------ ------------------------------------------------------------
  DPP-4 inhibitor vs metformin                                                                                                                                    
   Saxagliptin vs metformin                                                                                                                                       
    Saxagliptin                  406,876 (12,344.54)      5.965                        Higher cost                     Lower QALY                                 Dominated
    Metformin                    283,222 (8,592.90)       5.986                                                                                                   
   Sitagliptin vs metformin                                                                                                                                       
    Sitagliptin                  434,982 (13,197.27)      5.965                        Higher cost                     Lower QALY                                 Dominated
    Metformin                    283,222 (8,592.90)       5.986                                                                                                   
   Vildagliptin vs metformin                                                                                                                                      
    Vildagliptin                 428,869 (13,011.80)      5.965                        Higher cost                     Lower QALY                                 Dominated
    Metformin                    283,222 (8,592.90)       5.986                                                                                                   
  DPP-4 inhibitor vs SFU                                                                                                                                          
   Saxagliptin vs SFU                                                                                                                                             
    Saxagliptin                  406,876 (12,344.54)      5.965                        113,701 (3,449.67)              0.031                                      3,632,604 (110,212.50)
    SFU                          293,175 (8,894.87)       5.933                                                                                                   
   Sitagliptin vs SFU                                                                                                                                             
    Sitagliptin                  434,982 (13,197.27)      5.965                        141,806 (4,302.37)              0.031                                      4,530,556 (137,456.19)
    SFU                          293,175 (8,894.87)       5.933                                                                                                   
  Vildagliptin vs SFU                                                                                                                                             
   Vildagliptin                  428,869 (13,011.80)      5.965                        135,694 (4,116.93)              0.031                                      4,335,273 (131,531.34)
    SFU                          293,175 (8,894.87)       5.933                                                                                                   

**Abbreviations:** DPP-4, dipeptidyl peptidase-4; QALY, quality-adjusted life year; SFU, sulfonylurea; THB, Thai Baht.
